Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010

Diagnostic Microbiology and Infectious Disease

Volumn 70, Issue 4, 2011, Pages 507-511

  Hoban, Daryl J ^a   Nicolle, Lindsay E ^b   Hawser, Stephen ^c   Bouchillon, Samuel ^a   Badal, Robert ^a  

^a Division of Microbiology   (United States)

^b HEALTH SCIENCES CENTRE   (Canada)

^c International Health Management Associates Europe Sàrl   (Switzerland)

Author keywords

Escherichia coli; Surveillance; Urinary tract infection

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; FEMALE; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PACIFIC ISLANDS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HOSPITALS; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; URINARY TRACT INFECTIONS; WORLD HEALTH; YOUNG ADULT;

EID: 79960352692     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.03.021     Document Type: Article

References (24)

1. Alhambra A., Cuadros J.A., Cacho J., Gómez-Garcés J.L., Alós J.I. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J. Antimicrob. Chemother. 2004, 53:1090-1094.
2. CTX-M among Enterobacteriaceae in U.S. medical centers: molecular evaluation from the MYSTIC Program (2007). Microb. Drug Res. 2008, 14:211-216.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement (June 2010 update), document M100-S20-U 2010, CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement, document M100-S20 2010, CLSI, Wayne, PA.
5. Hawser S., Hoban D., Bouchillon S., Badal R., Carmeli Y., Hawkey P. Antimicrobial susceptibility of intra-abdominal Gram-negative bacilli from Europe: SMART Europe 2008. Eur. J. Clin. Microbiol. Infect. Dis. 2010, 30:173-179.
6. Hoban D.J., Bouchillon S.K., Hawser S.P., Badal R.E. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diagn. Microbiol. Infect. Dis. 2010, 66:78-86.
7. Jacobsen S.M., Stickler D.J., Mobley H.L.T., Shirliff M.E. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin. Microbiol. Rev. 2008, 21:26-59.
8. Karlowsky J.A., Hoban D.J., DeCorby M.R., Laing N.M., Zhanel G.G. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaboratory Alliance-Quinolone Resistance study. Antimicrob. Agents Chemother. 2006, 50:2251-2254.
9. Lewis J.S., Herrera M., Wickes B., Patterson J.E., Jorgensen J.H. First report of emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob. Agents Chemother. 2007, 51:4015-4021.
10. Livermore D.M., Canton R., Gniadkowski M., Nordmann P., Rossolini G.M., Arlet G., Ayala J., Coque T.M., Kern-Zdanowicz I., Luzzaro F., Poirel L., Woodford N. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 2007, 59:165-174.
11. Mathai D., Jones R.N., Pfaller M.A. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn. Microbiol. Infect. Dis. 2001, 40:129-136. the SENTRY Participant Group North America.
12. Mazzulli T. Resistance trends in urinary tract pathogens and impact on management. J. Urol. 2002, 168:1722.
13. Mohammadi M., Ghasemi E., Mokhayeri H., Pournia Y., Boroun H. Antimicrobial resistance patterns of E. coli detected from hospitalized urine culture samples. Asian J. Biol. Sci. 2010, 3:195-201.
14. Nicolle L.E., Strausbaugh L.J., Garibaldi R.A. Infections and antibiotic resistance in nursing homes. Clin. Microbiol. Rev. 1996, 9:1-17.
15. Olson R.P., Harrell L.J., Kaye K.S. Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections. Antimicrob. Agents Chemother. 2009, 53:1285-1286.
16. Paterson D.L., Bonomo R.A. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 2005, 18:657-686.
17. Pitout J.D.D., Laupland K.B. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 2008, 8:159-166.
18. Prakash V., Lewis J.S., Herrera M.L., Wickes B.L., Jorgensen J.H. Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 2009, 53:1278-1280.
19. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis. Mon. 2003, 49:71-82.
20. Souli M., Galani I., Giamerellou H. Emergency of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro. Surveill. 2008, 13. pii=19045.
21. Turnidge J., Bell J., Biedenbach D.J., Jones R.N. Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Antimicrobial Surveillance Program, 1998-1999. Int. J. Antimicrob. Agents. 2002, 20:10-17.
22. Urban C., Mariano N., Bradford P.A., Tuckman M., Segal-Maurer S., Wehbeh W., Grenner L., Colon-Urban R., Johnston B., Johnson J.R., Rahal J.J. Identification of CTX-M β-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn. Microbiol. Infect Dis. 2010, 66:402-406.
23. Zhanel G.G., DeCorby M., Adam H., Mulvey M.R., McCracken M., Lagacé-Wiens N.K.A., Wierzbowski A., Baudry P.J., Tailor F., Karlowsky J.A., Walkty A., Schweizer F., Johnson J., the Canadian Antimicrobial Resistance Alliance, Hoban D.J. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian ward surveillance study (CANWARD 2008). Antimicrob. Agents Chemother. 2010, 54:4684-4693.
24. Zhanel G.G., Hisanaga T.L., Laing N.M., DeCorby M.R., Nichol K.A., Weshnoweski B., Johnson J., Noreddin A., Low D.E., Karlowsky J.A., Hoban D.J. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int. J. Antimicrob. Agents 2006, 27:468-475. for the NAUTICA Group.